Combination Therapies

Spyre Therapeutics presented promising data at UEGW 2025 on SPY002, a potential IBD treatment. Phase 1 results showed SPY002 was well-tolerated, suppressed TL1A, and has a PK profile consistent with less frequent dosing. Preclinical data showed combination therapies (α4β7 + TL1A, α4β7 + IL-23, TL1A + IL-23) outperformed monotherapies in mouse models, supporting the ongoing SKYLINE-UC Phase 2 study. Analysts urge caution, emphasizing the need for clinical validation in later-stage trials.